ISRCTN15330757已完成不适用
A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pai
Cambridge Laboratories Ltd (UK)0 个研究点目标入组 100 人开始时间: 2007年9月12日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients entering the study will be recruited following written informed consent from pain clinics at participating centres
- •2. Patients will be in the age range 18 - 90 years with a diagnosis of neuropathic pain made according to the criteria set out below
- •3. Patients may be taking stable dose regimens of paracetamol, anticonvulsants, antidepressants, opioids or Non-Steroidal Anti-Inflammatory Srugs (NSAIDs)
- •4. Patients taking excluded medications (see exclusion criteria below) may enter the study after a two week period without these medications
- •Diagnosis of neuropathic pain:
- •The term neuropathic pain is loosely applied to a variety of heterogeneous conditions and strict diagnostic criteria are difficult to apply. However, for the purposes of this study, the diagnosis will be made on the basis of the following:
- •1. Pain secondary to an identifiable injury or disease process where damage to the central or peripheral nervous system is suspected
- •2. Pain persisting for more than three months in the absence of any continuing nociceptive stimulus
- •3. Pain that is documented as responding poorly to either opioid analgesics or NSAIDs
- •4. Pain associated with at least two of the following signs/symptoms:
- •4.1. Abnormal sensation on clinical examination, including sensory loss, paraesthesia, dysaesthesia
- •4.2. Mechanical allodynia (static or dynamic)
- •4.3. Pain of a burning character
- •4.4. Pain of a stabbing or lancinating character
- •4.5. Signs of sympathetic dysfunction (discolouration, abnormal vasomotor activity, skin trophic changes)
- •Many conditions may present with neuropathic pain. However, in some conditions the
- •distinction between primary nociceptive and neuropathic pain is extremely difficult. An
- •important example of this is in mechanical low back pain where radiation of pain into the legs is commonly reported in the absence of identifiable nerve injury. Given this diagnostic difficulty, for the purpose of this study, patients with lumbar radiculopathy will not be recruited to the study.
- •The Central Post-Stroke Pain Syndrome seems to have features that are significantly different to other types of neuropathic pain. For this reason, patients with this syndrome will not be included in this study.
排除标准
- •Patients may not enter the study if they have a history of any of the following conditions:
- •1. Epilepsy
- •2. Liver disease
- •3. Psychosis
- •4. Bipolar disorder
- •5. Substance misuse
- •6. Renal failure
- •7. Adverse reactions to either dihydrocodeine or nabilone
- •8. Pregnant women, lactating women or women of childbearing potential not using effective methods of contraception
- •9. Patients involved in ongoing legal action against a third party in which financial compensation is being sought for personal injury alleged to be the cause of the presenting condition
- •Excluded medications:
- •Patients may not take the following medications during the study:
- •1. Dihydrocodeine
- •2. Antipsychotic drugs
- •3. Benzodiazepine drugs (excepting stable doses of night-time sedatives)
- •4. Monoamine oxidase inhibitors
- •Patients taking dihydrocodeine may enter the study after a washout period of two weeks. Analgesia during this time will be provided with co-proxamol. Patients taking cannabinoid preparations of any kind may not be included in the study.
研究者
相似试验
已完成
不适用
A randomised, double-blind, crossover comparison of the efficacy and safety of study drug 017 and placebo in patients with neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN)ISRCTN33347454Purdue Pharma Canada70
进行中（未招募）
1 期
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.Attention-Deficit/Hyperactivity Disorder (AD/HD)MedDRA version: 23.0Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderSystem Organ Class: 100000004873EUCTR2006-001866-18-Outside-EU/EEAEli Lilly and Company
已完成
不适用
A clinical Study to Assess the safety and Efficacy of COCOZEN as a sports performance supplement in Healthy athletesCTRI/2018/03/012551Akay Flavours and Aromatics Private Limited48
已完成
不适用
Efficacy of prolonged-release melatonin versus placebo in a three-week treatment of diabetic patients suffering from insomniaISRCTN55944464eurim Pharmaceuticals Ltd. (Israel)36
进行中（未招募）
不适用
Comparison of the effects of two emollients in patients with dry skiDry eczematous skinMedDRA version: 18.0Level: PTClassification code 10013786Term: Dry skinSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2014-001026-16-GBDermal Laboratories Limited20